HK Stock Market Move | MEDBOT-B (02252) rises by more than 4% again, TiMai's global commercial installation surpasses 100 units, blooming both domestically and internationally.

MEDBOT-B (02252) rose more than 4%, as of the time of writing, it has increased by 3.67% to HKD 27.66, with a turnover of HKD 1.59 billion. In terms of news, on December 24, MEDBOT-B announced that based on preliminary internal statistics of the group, the total comprehensive order volume of the group's endoscopy, orthopedics, and vascular intervention core products has exceeded 230 units. Among them, the core product, the Siasun Robot & Automation (Tumai) endoscopic surgery system, has received commercial orders for over 160 units globally, with nearly 120 new orders received this year. According to public statistics, Tumai's global order volume for 2025 has ranked among the top two globally. In the domestic market, Tumai has made significant progress in top public hospitals and high-end private hospitals, with top 100 hospitals accounting for 23% of installations, and top-tier hospitals accounting for over 90%. Tumai has gradually formed a high-quality installation pattern driven by clinical value and professional capabilities. In the overseas market, Tumai has expanded its presence to over 40 countries and regions in Asia, Europe, Africa, Oceania, and South America, gaining recognition from local top institutions, and achieving "multi-unit sales, multi-hospital installations" in 15 countries, realizing the normalization, networking, and scale use within mature medical systems globally.